Our response and support

How you can help

Resources and trusted information

Society news and updates

COVID-19 safety at our events

Junior School (ages 7-11)

Senior school (ages 11-16)

Students (ages 16+)

Undergraduate

Postgraduate and early career

Clinical Pharmacology: for medical students

Beyond Medical School

School teacher or careers advisor

Pharmacology Educator

Where can pharmacology take me?

Case Studies

Finding Funding

Jobs & opportunities

Latest News

Blog

Events calendar

Propose an event

Sponsor our meetings & events

Abstracts guidance & advice

Bursaries

Code of conduct for meetings and events

COVID-19 safety at our events

List an event

About BPS education

Teaching pharmacology

Society training opportunities

Engagement

Ambassadors Scheme

Educational Resources

Clinical pharmacology

Prescribing and patient safety

Animal research

Why partner with the British Pharmacological Society?

Our reach

Partnership case studies

Our principles for working with commercial third-party partners

Get in touch

Blog

Pharmacology Matters

British Journal of Pharmacology

British Journal of Clinical Pharmacology

Pharmacology Research & Perspectives

Guide to PHARMACOLOGY

Become a peer reviewer

Society membership

Prizes, awards and grants

Awards Terms & Conditions

Bursaries

My BPS

Get involved

Documents and forms

Was 4β‐hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

Article date: July 2018

By: Sibylle Neuhoff, Geoffrey T. Tucker in Volume 84, Issue 7, pages 1620-1621

DOI: 10.1111/bcp.13538

View this article

Share this page

Previous

Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects

Next

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products

Publishing